NOTCH3 and lung disorder: 149). Therefore, while targeting of Notch3 expression with ASOs failed to reduce HDM-induced GCMH in adult mouse lungs (Ref. 103), this therapeutic approach may be more applicable for lung diseases like IPF and PAH where the role of NOTCH3 signalling in disease pathogenesis is more clearly defined.